Exact Sciences (STU:EXK) Minority Interest : €0.00 Mil (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Exact Sciences Minority Interest?

Minority interest is the carrying amount of the equity interests owned by non-controlling shareholders, partners, or other equity holders in one or more of the entities included in the reporting entity's consolidated financial statements.

Exact Sciences's minority interest for the quarter that ended in Mar. 2024 was €0.00 Mil.

Exact Sciences Minority Interest Historical Data

The historical data trend for Exact Sciences's Minority Interest can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exact Sciences Minority Interest Chart

Exact Sciences Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Minority Interest

Get a 7-Day Free Trial

Exact Sciences Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Minority Interest	Get a 7-Day Free Trial															-	-	-	-	-

Exact Sciences Minority Interest Calculation

Exact Sciences (STU:EXK) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Exact Sciences Corp (STU:EXK) » Definitions » Minority Interest

Comparable Companies

Traded in Other Exchanges

EXAS:USA

Address

5505 Endeavor Lane, Madison, WI, USA, 53719

Website

https://www.exactsciences.com

Exact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.